Gouault-Heilmann M, Huet Y, Adnot S, Contant G, Bonnet F, Intrator L, Payen D, Levent M
Haemostasis. 1987;17(3):134-40. doi: 10.1159/000215571.
Eight patients with a delayed-onset heparin-induced thrombocytopenia, with thrombotic complications requiring immediate anticoagulation in 7 of them, were given low molecular weight heparin (LMWH) fractions as alternative therapy. This treatment led to normalization of platelet count within 3-5 days in 6 patients with clinical recovery in 5. In 2 patients, thrombocytopenia persisted despite LMWH therapy. In vitro platelet aggregation tests performed in all patients gave evidence of a relationship between the presence (or absence) of a LMWH-dependent platelet-aggregating factor in the patients' plasma and the persistence (or correction) of the thrombocytopenia with LMWH therapy. Although positive in vitro tests may not necessarily be associated with thrombocytopenia, in vitro testing may prove to be a useful guide before giving LMWH fractions as an alternative therapy in patients with heparin-induced thrombocytopenia requiring immediate anticoagulation.
8例迟发性肝素诱导的血小板减少症患者，其中7例伴有血栓形成并发症需要立即抗凝，给予低分子量肝素（LMWH）片段作为替代治疗。该治疗使6例患者的血小板计数在3 - 5天内恢复正常，5例临床症状缓解。2例患者尽管接受了LMWH治疗，血小板减少症仍持续存在。对所有患者进行的体外血小板聚集试验表明，患者血浆中LMWH依赖性血小板聚集因子的存在（或不存在）与LMWH治疗后血小板减少症的持续（或纠正）之间存在关联。虽然体外试验呈阳性不一定与血小板减少症相关，但在需要立即抗凝的肝素诱导的血小板减少症患者中，在给予LMWH片段作为替代治疗之前，体外试验可能是一个有用的指导。
